Create an account

Already have an account?
Technical support
Send
The password is: uppercase and lowercase English letters and numbers, no less than 6 characters
Submit

Login

Don’t have an account? Sign up
Forgot password?
Login
Press Releases
All
  • All
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market

Xiamen, China, December 23, 2020 (12:30 pm) – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepo

AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide

AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide

Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.

AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award

AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award

The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).

AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market

AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market

Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market

Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.

AmoyDx Signs Agreement with AstraZeneca to Cooperate in Cancer Diagnosis in China

AmoyDx Signs Agreement with AstraZeneca to Cooperate in Cancer Diagnosis in China

Xiamen, China, 8 July, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that recently it signed an agreement with AstraZeneca to work together closely for the molecular diagnosis of patients with cancer.

AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market

AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market

Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The

AmoyDx Announces Research Collaboration with  Janssen to Develop Companion Diagnostics for China Market

AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market

Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology compa

Latest News: Amoy Diagnostics born another clinical detecting center

Latest News: Amoy Diagnostics born another clinical detecting center

Shanghai Xiawei Biotechnology Co. Laboratory (hereinafter referred to as "Shanghai Xiawei") under Amoy Diagnostics passed the examination of Shanghai Municipal Health Commission and was granted the "Practice License for Medical Institutions".

AmoyDx won the Second Prize of National Scientific and Technological Progress Award and National Enterprise Technology Center

AmoyDx won the Second Prize of National Scientific and Technological Progress Award and National Enterprise Technology Center

AmoyDx won the Second Prize of National Scientific and Technological Progress Award; AmoyDx Technology Center is qualified as "National Enterprise Technology Center".

AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement

AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement

Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies i

AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection

AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection

Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.

AmoyDx Lung Cancer PCR Panel accepted into LC-SCRUM as Screening Test for Pharma Clinical Trials in Japan

AmoyDx Lung Cancer PCR Panel accepted into LC-SCRUM as Screening Test for Pharma Clinical Trials in Japan

Xiamen, China — September 30, 2019 -- Amoy Diagnostics Co., Ltd (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that the AmoyDx Lung Cancer PCR Panel has been accepted as first-line screening for p

AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network

AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and with PREMIA Holdings (HK) Ltd.

Breaking News! ROS1, EGFR included on health insurance list of SK, TW

Breaking News! ROS1, EGFR included on health insurance list of SK, TW

Breaking News! South Korea Includes AmoyDx® ROS1 Kit on National Health Insurance List Taiwan, China Includes AmoyDx® EGFR Kit on Health Insurance List

AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority

AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit approved by Chinese Authority

AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit was approved by Chinese National Medical Products Administration (NMPA) on February 27, 2019, intended for qualitative detection of gene BRCA1 and BRCA2 mutation in patients with different cancer types  

Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau

Sanomics Limited and Amoy Diagnostics Partner to Deliver Multi-Gene Tests in Hong Kong and Macau

Xiamen, 28 January 2019 – Amoy Diagnostics Co., LTD., a leading company focusing on molecular diagnostics for precision oncology, and Sanomics Limited, a pioneering company in providing genomics tests in

AmoyDx ROS1 Kit Approval in Taiwan, China

AmoyDx ROS1 Kit Approval in Taiwan, China

Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan, China Food and Drug Administration(TFDA).

Subscribe
to our
newsletter

Subscribe to our newsletter

Subscribe Now